Sort   by:  
 Page size 
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Chemical Proteomics Cal51
PARP1 inhibitors (PARP1is) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, o...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020520 | Pride
Adavosertib Parp16 Breast cancer Parp1 Polypharmacology Parp inhibitor Proteomics Off-target Talazoparib 
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Chemical Proteomics
PARP1 inhibitors (PARP1is) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, o...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020455 | Pride
Adavosertib Parp16 Lung cancer Parp1 Polypharmacology Parp inhibitor Ewing’s sarcoma Proteomics Off-target Talazoparib 
ProteomicsPARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib
The synthetic lethal association between BRCA deficiency and poly (ADP-ribose) polymerase (PARP) inhibition supports PARP inhibitor (PARPi) clinical efficacy in BRCA-mutated tumors. PARPis also demonstrate activity in non-BRCA mutated tumors presumably through induction of PARP1-DNA trapping. Despit...
ORGANISM(S): Homo sapiens (Human) 
2022-07-08 | PXD033530 | Pride
Parp1 Drug resistance Talazoparib 
GenomicsRNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib
RNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib
PRJNA515518 | ENA
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Phosphoproteomics
PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, ...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020484 | Pride
Adavosertib Phosphoproteomics Parp16 Lung cancer Parp1 Polypharmacology Parp inhibitor Ewing’s sarcoma Off-target Talazoparib 
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Expression Proteomics
PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, ...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020485 | Pride
Adavosertib Parp16 Parp1 Small cell lung cancer Polypharmacology Parp inhibitor Proteomics Off-target Talazoparib 
TranscriptomicsRNAseq analysis of BRCA deficient tumors treated with saline, Nano-Talazoparib or Talazoparib
We report the gene expression profile in BRCA deficient tumors after treatment with saline, nanoparticle-formulated Talazoparib and free Talazoparib
ORGANISM(S): Mus musculus 
2020-04-10 | GSE125206 | GEO
GenomicsQuantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line
Quantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line
PRJNA661301 | ENA
TranscriptomicsQuantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line
To explore the molecular mechanisms by which romidepsin potentiates the effect of talazoparib, RNA sequencing analysis of MBL2 cell lines treated with talazoparib, romidepsin, or talazoparib plus romidepsin was performed. 40% of the 2023 genes in combination were from talazoparib, whereas only 5.9% ...
ORGANISM(S): Mus musculus 
2020-09-04 | GSE157434 | GEO
GenomicsPARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib (scRNA-Seq)
PARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib (scRNA-Seq)
PRJNA836116 | ENA
Sort   by:  
 Page size